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Abstract
Background: We previously demonstrated improved sweating after enzyme replacement therapy
(ERT) in Fabry disease using the thermo-regularity sweat and quantitative sudomotor axon reflex
tests. Skin-impedance, a measure skin-moisture (sweating), has been used in the clinical evaluation
of burns and pressure ulcers using the portable dynamic dermal impedance monitor (DDIM)
system.
Methods: We compared skin impedance measurements in hemizygous patients with Fabry disease
(22 post 3-years of bi-weekly ERT and 5 ERT naive) and 22 healthy controls. Force compensated
skin-moisture values were used for statistical analysis. Outcome measures included 1) moisture
reading of the 100th repetitive reading, 2) rate of change, 3) average of 60–110th reading and 4)
overall average of all readings.
Results: All outcome measures showed a significant difference in skin-moisture between Fabry
patients and control subjects (p < 0.0001). There was no difference between Fabry patients on ERT
and patients naïve to ERT. Increased skin-impedance values for the four skin-impedance outcome
measures were found in a small number of dermatome test-sites two days post-enzyme infusions.
Conclusion: The instrument portability, ease of its use, a relatively short time required for the
assessment, and the fact that DDIM system was able to detect the difference in skin-moisture
renders the instrument a useful clinical tool.
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Fabry disease is an X-linked lysosomal disorder caused by
a deficiency of alpha-galactosidase A (GALA) resulting in
accumulation of alpha-D-galactosyl conjugates, particu-
larly globotriosylceramide in a variety of cell types [1,2],
including dorsal root ganglia [3]. The diagnosis of Fabry
disease is often made on clinical suspicion because of the
presence of skin lesions (angiokeratoma) or corneal opac-
ities that do not affect visual acuity. Other methods of
diagnosis including a family pedigree ascertainment tak-
ing into account a history of renal failure or stroke of early
onset, i.e. less than 50 years of age [4]. The demonstration
of deficient GALA enzyme activity in white blood cells of
hemizygous males or identification of a pathognomonic
mutation in a heterozygous female confirms the diagnosis
[5,6]. Neuropathic pain and hypohidrosis may also con-
tribute to reduced exercise capacity and heat intolerance
[7].
Extensive lipid accumulation within neurons of the auto-
nomic nervous system may be the pathologic basis for
neuropathic pain, diminished sweating, and other auto-
nomic signs of this disorder. Enzyme replacement therapy
(ERT) for Fabry disease has shown to be promising for
adult hemizygous patients in the context of stabilizing
renal disease and reversing less life-threatening symptoms
such diarrhea [8,9].
We previously demonstrated improved sweating in adult
male Fabry patients treated with ERT using thermo-regu-
larity sweat testing (TST) and quantitative sudomotor
axon reflex test (QSART) [10]. Both of these tests are diffi-
cult to implement in a routine clinical setting [11-13]. A
more convenient clinical instrument allowing estimation
of skin moisture uses dynamic dermal impedance
(DDIM). "Impedance" is the resistance to the flow of an
alternating current and is influenced by skin-moisture.
The DDIM system is a portable instrument with force
compensation to allow measurement of skin-moisture.
DDIM has been used in the clinical setting to assess skin-
moisture [14,15], but never in Fabry disease.
Here, we report the ascertainment of skin moisture across
surface dermatomes by DDIM in patients with Fabry dis-
ease compared to healthy control subjects [15-17].
Methods
Subjects
Twenty-two adult male patients with Fabry disease who
were after 3 years of ERT (mean age: 40.6 ± 8.1 years), five
ERT-naïve patients with Fabry disease (mean age: 33.8 ±
8.0 years), and 22 control subjects (mean age: 36.0 ± 14.1
years) participated in this study. All but two were non-His-
panic Caucasians. Fabry disease was confirmed by GALA
enzyme assays. The clinical manifestations of patients on
ERT have been described previously in detail [18]. All the
patients in this study had neuropathic pain and hypohid-
rosis.
The healthy control subjects were recruited through the
National Institutes of Health Clinical Research Volunteer
Program. They were interviewed and examined by the
investigator and were confirmed as clinically and neuro-
logically normal.
The Institutional Review Board of the National Institute of
Neurological Disorders and Stroke at the National Insti-
tutes of Health approved this study. All patients and
healthy control subjects gave their written informed con-
sent prior to their inclusion in this study.
GALA enzyme: production and treatment regimen
The α-galactosidase A enzyme used in this study (agalsi-
dase alfa, Replagal®) was produced in a genetically engi-
neered continuous human cell line (Shire Human Genetic
Therapies, Cambridge, MA, USA). It was administered at a
dose of 0.2 mg/kg of body weight by intravenous infusion
over a period of 40 minutes at a frequency of every other
week [18]. Patients who were on ERT for three years were
studied just before enzyme infusion (defined as pre-infu-
sion) and two days after enzyme infusion (defined as
post-infusion).
Dynamic dermal impedance monitor (DDIM) (Petite)
The Petite system DPM 9003 (NOVA Technology Corpo-
ration, Portsmouth, NH, USA) was used to assess the skin-
impedance as a surrogate for skin moisture. [19].
Testing and data collection
Fabry patients on ERT (22 patients) and ERT-naïve (5
patients) were studied twice (before and two days after
their ERT infusion or two days after the initial measure-
ment for those who were not on ERT). Skin moisture of
healthy controls was measured only once. All tests were
performed in the same room with controlled temperature
and humidity. Temperature and humidity were recorded
throughout the testing.
The hand-held DDIM probe connected to a personal dig-
ital assistant (PDA) was placed in a specific sequence on
test-sites 1 through 26, corresponding to the cutaneous
dermatomes from face to feet as shown in Figure 1. The
recorded data were transferred from the PDA to a personal
computer for subsequent analysis.
For each of 26 test-sites, the DDIM System recorded and
displayed five columns of data; Column 1 – Time incre-
ment (five readings per second), Column 2 – Force-com-
pensated moisture value (Dermal Phase Meter, DPM),
Column 3 – Force applied (in grams), Column 4 – SkinPage 2 of 7
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compensated moisture value. All five values were pro-
vided for approximately 0 – 120 readings. Only Column
2 data of force-compensated moisture values, for 1st–
110th recordings, at the 26 sites of each subject were used
for statistical analysis. The parameter 'force-compensated
moisture' was chosen because it provides a uniform appli-
cation of the skin impedance probe from subject to sub-
ject and within a subject. The probe force compensation
provides increased uniformity of measurement and there-
fore a reduced variance of the measurements.
A typical skin-impedance measurement value graph aver-
aged across all 26 sites for Control group (n = 22) is
shown in Figure 2.
Creation of outcome measures
Four outcome measures were created to analyze various
aspects of the force-compensated impedance values. The
designs of the outcomes were intended to account for fact
that there were 110 readings for each patient at each of 26
test-sites and to account for the distribution of the read-
ings over time in four different ways (see Figure 2). The
definition of each outcome measures is as follows:
1). Reading 100 (R100): The moisture reading of the 100th
of the 110 readings. This measure is designed to capture
the extreme time values of the readings.
2). Rate of Change: Generally the moisture measurements
increased from the 1st to the 110th for each reading. The
rate of change or chord-slope of this increase was captured
by taking the average of the first 10 readings (R = 1, 2...10)
and subtracting it from the average of the last 10 readings
(R = 100,102...110). Averages were taken at the beginning
and end of the sample to make the measure resistant to
outliers and large variations.
3). Average 60+: Of the 110 readings the 1st through 59
readings were ignored and the rest (60–110) were aver-
aged.
4). Overall Average: All 110 readings were combined into
the mean.
Statistical Analysis
SPSS version 14 (SPSS Inc, Chicago, IL, USA) was used for
all analysis. Comparisons between groups were per-
formed through ANOVA with Tukey post-hoc multiple
comparisons. Tests using control variables for adjustment
of differences were done using Generalized Linear Mod-
els. Tests of pre-versus post-ERT were performed using the
paired two-sample t-test.
Testing Environment
All subjects had normal skin temperature. Although the
total difference in temperatures for the pre-infusion
between the 3 subject groups (controls, pre-ERT-naïve and
Fabry on ERT) differed by a maximum of 1.3°F, this small
difference was statistically significant (p = 0.019). A simi-
lar situation occurred for pre-infusion humidity, post-ERT
temperature, and post-infusion humidity (p = 0.043, p =
0.015, and p = 0.006, respectively).
Results
All created outcomes, (R100, Rate of Change, Average 60+
and Overall Average), showed similar significant differ-
ences (p < 0.0001) in skin-impedance values between
Fabry patients and control subjects for most test-sites.
Based on p-values, sites 19 through 24 provided inconsist-
ently small p-values in all four measures,, while sites 25
Neuro-anatomical dermal test sites used for the skin-imped-ance testingFig r  1
Neuro-anatomical dermal test sites used for the skin-
impedance testing. The PDA probes were placed on spe-
cific locations on the body as marked by the bullets in the fig-
ure. Note the corresponding test sites are not shown on the 
left side of the body. The letter and number within the 
bracket indicate the specific cutaneous nerve distribution.Page 3 of 7
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This box plot of an Overall Average skin-moisture value in DPM units at right ophthalmic nerve distribution (test site 1) for three Groups f subject shows the difference in skin-mo sture values between healthy controls and Fabry pati n sFigure 2
This box plot of an Overall Average skin-moisture value in DPM units at right ophthalmic nerve distribution 
(test site 1) for three Groups of subject shows the difference in skin-moisture values between healthy controls 
and Fabry patients. No difference in skin-moisture values between Fabry ERT-naïve and Fabry patient on enzyme replace-
ment therapy was discerned.
Table 1: Tukey Post-hoc Results for Between Group Differences for one of the four created Overall Average skin-moisture outcome 
measures value at test-site 1, (right ophthalmic cutaneous nerve distribution)
Patient Group (I) Patient Group (J) Mean Difference (I-J) Std. Error Sig.
Control Fabry ERT1-naïve 128.455(*) 37.638 0.004
Fabry with ERT 132.636(*) 22.906 0.000
ERT-naïve Fabry Control -128.455(*) 37.638 0.004
Fabry with ERT 4.182 37.638 0.993
Fabry with ERT Control -132.636(*) 22.906 0.000
Fabry ERT-naïve -4.182 37.638 0.993
Groups listed in "I" are compared to each in "J" and a significantly different mean is determined by the p-value shown in the "Sig" column.
1Enzyme Replacement Therapy
(*) Significant at 0.01 levels
BMC Neurology 2008, 8:41 http://www.biomedcentral.com/1471-2377/8/41and 26 did not provide useful data for the Rate of Change
parameter.
As a representative example, a box plot of the Overall
Average moisture value at test-site 1 for three groups of
subjects is shown in Figure 2. These differences persisted
in the other three outcome measures (R100, Rate of
Change and Average 60+), even after controlling for age,
pre-infusion temperature differences and pre-infusion
humidity differences as covariates, (p < 0.0001).
Since the control group is statistically independent of the
four outcome measures, we used a simple ANOVA analy-
sis incorporating all the sites and a Tukey Post-hoc analy-
sis to show that no significant difference appeared
between Fabry on ERT and Fabry naïve to ERT patients
groups (Table 1).
GALA Enzyme Models
There is a strong relation between the enzyme levels and
group membership (p < 0.0001). Therefore, to avoid co-
linearity problems with the model, we could not put both
patient group and residual enzyme levels in the same
model. Interestingly, when this attempt was made,
enzyme level significantly predicted skin-impedance lev-
els and patient group did not (p = 0.048, p = 0.52 respec-
tively for Overall Average at Site 1). This indicates that
enzyme levels predict skin moisture levels better than the
patient groups. With enzyme levels replacing patient
group in the model (removed patient groups), enzyme
levels were significantly related to skin moisture values
even after controlling for temperature and humidity (p <
0.0001).
Pre-versus Post-ERT testing Skin-moisture values
Analysis of pre-infusion and post-infusion skin-imped-
ance demonstrated no significant fixed effect attributable
to ERT. A paired two-sample t-test was performed compar-
ing pre-infusion and post-infusion scores at each site for
each of the four created outcome measures. Test-site 2
(Left V1) is the only site that showed a significant differ-
ence between pre- and post-infusion moisture. However,
this was only true for T-100 (p = 0.029), Average 60+ (p =
0.022), and Overall Average (p = 0.024), but not Rate of
Change (p = 0.383). The matched site, Site1 (Right V1),
was not significant for any of the outcome measures. The
test-site 19 (Right L2) was significantly different in only
the Rate of Change case with a decrease in skin-imped-
ance. Recall that Site 19 also was the poorest performer
otherwise.
Discussion
The observed difference in skin-moisture values between
healthy controls and Fabry patients is not surprising but it
is important to note that the DDIM system was able to
detect such a difference. In comparison with QSART, in
which sweat function improved 24–72 hours after
enzyme infusion, normalized in four patients and seven
patients remained non-responders [10]. The DDIM sys-
tem did not show improvements either 2 weeks after infu-
sion, or 2 days after infusion in Fabry patients. The small
sample size may explain the lack of difference in skin-
moisture values between ERT-naïve patients and Fabry
patients on ERT which may have implications for the use
of skin-impedance in clinically monitoring ERT efficacy.
Since all Fabry patients on ERT had fortnightly enzyme
infusions over three years prior to this study, it seems that
ERT does not have a cumulative effect on skin-impedance
if one assumes that the pre-treatment values of the treated
group were similar to the five ERT naïve patients. This is
particularly obvious in pre- and two days post-ERT testing
in Fabry patients.
Since each of the created outcome measures showed no
particular performance advantage over the R100 outcome
measure, we recommend the R100 measure due to its con-
venience in the clinical setting. Use of the R100 outcome
requires that the user of the DDIM System need only
needs to record a single skin-moisture reading (100th read-
ing of 110). This avoids having to use complicated data-
base software and hours of programming to format the
text data into summary information required for each of
the other measures. However, it would be necessary to
prospectively validate this index.
Specific Dermal Test-site
In an analysis of test-sites, only a few sites performed
poorly with R100 (sites 19 through 24). So, the investiga-
tor can choose any of the test-sites from 1–23 as a test-site
on the subject body. We recommend the three most acces-
sible dermatomes as test sites for use in Fabry disease; Site
1 (Face, right V1), Site 7 (Neck, right T2) and Site 17
(Hand, right radial). The median value from these three
readings sites could be taken as an representative value of
the overall skin impedance in a given patient in order to
reduce the measurement variability
Our results of skin-moisture values between Fabry
patients and control subjects are consistent with previous
studies of TST and QSART in Fabry disease [10,11]. But
unlike previous studies, this study failed to show an acute
improvement in skin-moisture in post-ERT Fabry patients
who had received ERT over three years periodically. This
could be due to fact that the DDIM system, unlike previ-
ous studies, assesses the base level of skin-moisture and
not thermal or chemical induced skin-moisture (sweat-
ing). The importance of measuring either base or induced
skin-moisture is not known but may be explored. Because
the therapeutic effect of ERT (assessed as a function of
sweating) lasted for about 7 days with subsequent returnPage 5 of 7
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ascertainment of post-infusion skin-moisture response in
the current study may be improved by recording an
induced skin-moisture response over an extended period.
GALA enzyme and skin-moisture
The statistical relationship of residual GALA enzyme levels
to skin-moisture in the analysis model value further cor-
roborates a known association of hidrosis and residual
GALA enzyme activity in Fabry disease. Patients with
residual enzyme activity have milder disease, and normal
or close to normal sweating [20]. Future study should
explore whether an improvement in skin-impedance
translates to improvement in other pathophysiological
functions [21,22].
Although there was a statistically significant difference in
environmental parameters by subjects group, the skin-
impedance outcome measures were not affected. This was
most likely due to the small magnitude of the environ-
mental differences. However, efforts should be made to
assure an adequate control of temperature and humidity
in the testing environment in subsequent studies.
Limitations of the study
The main limitation of this study was the lack of randomi-
zation and a lack of serial post-infusion testing. Although
the DDIM instrument is designed to adjust for the pres-
sure applied on skin surface and there is a built in indica-
tor for a lack of proper skin contact, there was still
evidence of significant variance in skin-impedance record-
ing across dermatome sites. This is a further reason for the
three test-sites recommendation for any given patient
with the median value to be used in subsequent analysis.
The DDIM system is a static technique but demonstrates
the extent of the skin abnormality at a level not previously
documented in Fabry disease. The diagnostic potential of
skin impedance in Fabry has not been explored but since
the technique could potentially provide the busy clinician
with a screening instrument for Fabry, further studies are
indicated.
Conclusion
Difference in skin-impedance between control and Fabry
patients on ERT, and a non-significant difference between
Fabry patients on ERT and Fabry ERT-naïve patients as
assessed by DDIM system were demonstrated. To capture
an optimum skin-moisture (sweating) with a minimum
recording and also for data analysis ease, a median record-
ing of R100 outcome measure over three test-sites on the
right side of the body, Site 1 (Face; V1), Site 7 (Neck; T2)
and Site 17 (Hand; radial) is recommended. Skin-imped-
ance outcome measures failed to detect improvement in
skin-moisture levels after two days interval testing in
Fabry patients before and after ERT infusion. This may be
due to the fact that unlike TST and QSART, the DDIM sys-
tem assesses the base level of skin-moisture and not an
induced sweating.
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